Seeing Is Believing
Currently out of the existing stock ratings of Daniil Gataulin, 19 are a BUY (73.08%), 7 are a HOLD (26.92%).
Analyst Daniil Gataulin works at CHARDAN CAPITAL with a stock forecast success ratio of 28.57% fulfilled within 108.86 days on average.
Daniil Gataulin’s has documented 48 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RGNX, Regenxbio at 07-Mar-2024.
Analyst best performing recommendations are on EYPT (EYEPOINT PHARMACEUTICALS).
The best stock recommendation documented was for ADVM (ADVERUM BIOTECHNOLOGIES) at 11/11/2022. The price target of $2 was fulfilled within 243 days with a profit of $1.23 (159.74%) receiving and performance score of 6.57.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
4
$-10.66 (-72.71%)
2
1 months 22 days ago
4/4 (100%)
$1.5 (60.00%)
279
Buy
6
$4.05 (207.69%)
4
6 months 22 days ago
4/7 (57.14%)
$4.22 (237.08%)
196
Buy
4
$-10.66 (-72.71%)
2
7 months 17 days ago
4/4 (100%)
$2.11 (111.64%)
432
Hold
3
$-11.66 (-79.54%)
6
1 years 4 months 17 days ago
3/4 (75%)
$2.23 (289.61%)
528
Hold
2
$-12.66 (-86.36%)
5
2 years 8 months 5 days ago
3/3 (100%)
$-0.36 (-15.25%)
397
Which stock is Daniil Gataulin is most bullish on?
What Year was the first public recommendation made by Daniil Gataulin?